查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602136

全球干细胞治疗市场：按类型、细胞来源、治疗应用、最终用户分类 - 2025-2030 年预测

Stem Cell Therapy Market by Type, Cell Source, Therapeutic Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年干细胞治疗市值为4.3983亿美元，预计2024年将达到4.9323亿美元，复合年增长率为12.88%，到2030年将达到10.2744亿美元。

干细胞疗法代表了医学创新的一个变革领域，利用未分化的细胞取代体内受损或患病的细胞，治疗帕金森氏症、糖尿病和心臟病等多种慢性疾病，为疾病提供了潜在的治疗方法。 。干细胞疗法透过针对复杂且以前无法治疗的疾病状态来解决未满足的医疗需求，这是再生医学的革命性方法。最终用途涵盖医院、研究机构和专科诊所，治疗领域从肿瘤学到脊髓治疗。该市场主要受到干细胞研究技术进步、人口老化导致慢性病盛行率增加以及公共和私营部门投资增加等因素的显着推动。随着个人化医疗越来越被接受，再生治疗有可能缩短復原时间并提高生活品质，机会比比皆是。然而，围绕胚胎干细胞使用的伦理问题、高昂的治疗成本和严格的法律规范仍然是市场成长的主要挑战。也存在局限性，包括治疗结果的可变性和长期临床试验的复杂性。为了利用市场机会并缓解这些限制，技术创新应专注于开拓具有成本效益的同种异体细胞治疗方法和优化自体干细胞应用。需要进一步的研究，包括改进冷冻保存技术和改善细胞分化过程。生物技术公司、学术机构和政府机构之间的合作创造了一个实现突破的生态系统。此外，透过教育宣传活动提高公众意识和接受度可以减轻道德担忧并提高市场渗透率。总体而言，市场格局呈现出一种充满活力的局面，由巨大的成长潜力支撑，并受到监管、道德和技术挑战的调节，需要采取可持续发展的策略方法。

主要市场统计
基准年[2023] 4.3983亿美元
预测年份 [2024] 4.9323 亿美元
预测年份 [2030] 10.2744亿美元
复合年增长率（%） 12.88%

市场动态：揭示快速发展的干细胞治疗市场的关键市场洞察

供需的动态交互作用正在改变干细胞治疗市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 全球退化性疾病和癌症患者数量不断增加
    • 世界各地政府加强对干细胞治疗的力度
    • 扩建干细胞治疗中心和诊所
  • 市场限制因素
    • 实施干细胞疗法的困难
  • 市场机会
    • 干细胞治疗的持续进展
    • 干细胞治疗和治疗的营销核准和临床试验迅速增加
  • 市场挑战
    • 使用干细胞治疗的伦理和安全问题

波特五力：驾驭干细胞治疗市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解干细胞治疗市场的外部影响

外部宏观环境因素在塑造干细胞治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解干细胞治疗市场的竞争状况

干细胞治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位基质干细胞治疗市场供应商绩效评估

FPNV定位矩阵是评估干细胞治疗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。四个象限清楚且准确地划分供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

本报告提供了涵盖关键重点领域的全面市场分析：

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地退化性疾病和癌症的发生率正在上升
      • 世界各地政府围绕干细胞治疗的措施增加
      • 扩建干细胞治疗中心和诊所
    • 抑制因素
      • 实施干细胞治疗的困难
    • 机会
      • 干细胞治疗的持续进展
      • 干细胞治疗方法的销售和临床试验核准激增
    • 任务
      • 干细胞治疗的伦理与安全问题
  • 市场区隔分析
    • 类型：在慢性病治疗中越来越多地使用同种异体和自体干细胞疗法
    • 细胞来源：AD-MSC 和 BM-MSC 在组织重塑和组织修復的应用越来越多
    • 治疗应用：再生医学在各个治疗领域越来越受欢迎
    • 最终用户：学术研究中心和医院更多地使用干细胞治疗，提供有效、安全和标准化的治疗结果
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章干细胞治疗市场：依类型

  • 同种异体干细胞疗法
  • 自体干细胞治疗

第七章干细胞治疗市场细胞来源

  • 脂肪组织来源的 MSC
  • 骨髓间质干细胞
  • 胎盘/脐带来源的 MSC

第八章依治疗应用分類的干细胞治疗市场

  • 心血管疾病手术
  • 发炎与自体免疫疾病
  • 肌肉骨骼疾病
  • 神经系统疾病
  • 整形外科和风湿病学
  • 伤口和伤害

第九章干细胞治疗市场：依最终使用者分类

  • 学术研究中心
  • 门诊手术中心
  • 生物技术和製药公司
  • 医院/诊所

第十章美洲干细胞治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太干细胞治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲干细胞治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • FUJIFILM投资2亿美元用于细胞疗法生产
    • FDA 拒绝后 Mesoblast 开始合作进行 SR-aGVHD 试验
    • Selecta Biosciences 宣布与 Cartesian Therapeutics 合併
    • Takara Bio 与 Fondazione Telethon ETS 签署 RetroNectin授权合约
    • 拜耳开设第一家细胞疗法製造工厂，推动全球再生医学发展
    • 诺和诺德基金会投资1.35亿美元建造细胞治疗工厂
    • BioLineRx 宣布 FDA核准APHEXDA（莫替沙福肽）与Filgrastim（G-CSF）联合用于多发性骨髓瘤患者的造血干细胞采集和随后的自体移植
    • BlueRock Therapeutics 和 bit.bio 宣布就基于调节性 T 细胞 (Treg) 的治疗方法的发现和製造达成合作和选择权协议
    • StemCyte与美国领先的免疫细胞治疗公司签署合作协议，为同种异体工程细胞疗法提供药物製造原料
    • CIRM 投资 8,900 万美元用于干细胞和基因治疗研究
    • 百时美施贵宝在美国开设新的病毒载体生产工厂，增强细胞治疗能力
    • 诺和诺德扩大在大波士顿地区的研发足迹
    • Garuda Therapeutics 获得 6,200 万美元 B 轮资金筹措，用于推进现成的血液干细胞技术平台
    • BioCardia 和 CellProthera 加强合作，开发 ProtheraCytes，用于治疗欧洲的急性心肌梗塞，并有可能为患者提供早期治疗机会
    • ReLive Biotechnologies Ltd. 完成对 Co.Don AG 资产的收购和 SHC主导的A 轮资金筹措，进一步实现成为再生治疗全球参与者的雄心

公司名单

  • 4D Molecular Therapeutics, Inc.
  • Anterogen Co., Ltd.
  • Astellas Pharma Inc.
  • Athersys, Inc.
  • Aurion Biotechnologies
  • Beike Biotechnology Co., Ltd.
  • BrainStorm Cell Therapeutics Inc.
  • Bristol-Myers Squibb Company
  • CellProthera
  • Fate Therapeutics, Inc.
  • Gamida Cell Ltd.
  • Garuda Therapeutics
  • Holostem Terapie Avanzate Srl
  • Jasper Therapeutics, Inc.
  • JCR Pharmaceuticals Co., Ltd.
  • Juvena Therapeutics Inc.
  • Kangstem Biotech., Ltd.
  • Kite Pharma, Inc. by Gilead Sciences, Inc.
  • Lineage Cell Therapeutics, Inc.
  • Lonza Group AG
  • Mesoblast Ltd.
  • Novo Nordisk A/S
  • Plasticell
  • ReNeuron Group PLC
  • Sartorius CellGenix GmbH
  • SQZ Biotechnologies Company
  • Takara Bio Inc.
  • US Stem Cell Inc
  • Umoja Biopharma
  • Vericel Corporation
Product Code: MRR-431752EA49AD

The Stem Cell Therapy Market was valued at USD 439.83 million in 2023, expected to reach USD 493.23 million in 2024, and is projected to grow at a CAGR of 12.88%, to USD 1,027.44 million by 2030.

Stem cell therapy represents a transformative area in medical innovation, where undifferentiated cells are used to replace damaged or diseased cells in the body, offering potential cures for various chronic illnesses such as Parkinson's, diabetes, and heart diseases. The necessity for stem cell therapy arises from its ability to address unmet medical needs by targeting complex and previously untreatable conditions, making it a revolutionary approach in regenerative medicine. Applications range from oncology to spinal cord treatments, with end-use spanning across hospitals, research institutes, and specialized clinics. The market is significantly driven by factors such as technological advancements in stem cell research, an aging population leading to increased prevalence of chronic conditions, and growing investments from both public and private sectors. Opportunities are abundant with the increasing acceptance of personalized medicine and the potential for regenerative treatments to shorten recovery times and enhance life quality. However, ethical concerns surrounding embryonic stem cell use, high treatment costs, and stringent regulatory frameworks remain prominent challenges to market growth. Limitations also include variability in treatment outcomes and the complexity of long-term clinical trials. To capitalize on market opportunities and mitigate these constraints, innovation should focus on developing cost-effective allogenic treatments and optimizing autologous stem cell applications. Further research is warranted in enhancing cryopreservation techniques and improving cell differentiation processes. Collaborations between biotech firms, academic institutions, and government bodies can foster an ecosystem primed for breakthroughs. Moreover, increasing public awareness and acceptance through educational campaigns could alleviate ethical concerns and drive market penetration. Overall, the stem cell therapy market presents a dynamic landscape underpinned by significant growth potential tempered by regulatory, ethical, and technical challenges that necessitate strategic approaches for sustained advancement.

KEY MARKET STATISTICS
Base Year [2023] USD 439.83 million
Estimated Year [2024] USD 493.23 million
Forecast Year [2030] USD 1,027.44 million
CAGR (%) 12.88%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Stem Cell Therapy Market

The Stem Cell Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of degenerative diseases and cancer cases across the world
    • Increasing government initiatives for stem cell therapy across the world
    • Expansion of stem cell therapy centers and clinics
  • Market Restraints
    • Difficulties associated with performing stem cell therapy
  • Market Opportunities
    • Ongoing advancements in stem cell therapy
    • Surging approvals for marketing and clinical trials for stem cell therapies and treatments
  • Market Challenges
    • Ethical and safety issues of stem cell-based therapy

Porter's Five Forces: A Strategic Tool for Navigating the Stem Cell Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Stem Cell Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Stem Cell Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Stem Cell Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Stem Cell Therapy Market

A detailed market share analysis in the Stem Cell Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Stem Cell Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Stem Cell Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Stem Cell Therapy Market, highlighting leading vendors and their innovative profiles. These include 4D Molecular Therapeutics, Inc., Anterogen Co., Ltd., Astellas Pharma Inc., Athersys, Inc., Aurion Biotechnologies, Beike Biotechnology Co., Ltd., BrainStorm Cell Therapeutics Inc., Bristol-Myers Squibb Company, CellProthera, Fate Therapeutics, Inc., Gamida Cell Ltd., Garuda Therapeutics, Holostem Terapie Avanzate S.r.l., Jasper Therapeutics, Inc., JCR Pharmaceuticals Co., Ltd., Juvena Therapeutics Inc., Kangstem Biotech., Ltd., Kite Pharma, Inc. by Gilead Sciences, Inc., Lineage Cell Therapeutics, Inc., Lonza Group AG, Mesoblast Ltd., Novo Nordisk A/S, Plasticell, ReNeuron Group PLC, Sartorius CellGenix GmbH, SQZ Biotechnologies Company, Takara Bio Inc., U.S. Stem Cell Inc, Umoja Biopharma, and Vericel Corporation.

Market Segmentation & Coverage

This research report categorizes the Stem Cell Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Allogeneic Stem Cell Therapy and Autologous Stem Cell Therapy.
  • Based on Cell Source, market is studied across Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, and Placental / Umbilical Cord-Derived MSCs.
  • Based on Therapeutic Application, market is studied across Cardiovascular Diseases Surgeries, Inflammatory & Autoimmune Diseases, Musculoskeletal Disorders, Neurological Disorders, Orthopedics & Rheumatoid, and Wounds & Injuries.
  • Based on End-User, market is studied across Academic & Research Centers, Ambulatory Surgical Centers, Biotechnology & Pharmaceutical Companies, and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of degenerative diseases and cancer cases across the world
      • 5.1.1.2. Increasing government initiatives for stem cell therapy across the world
      • 5.1.1.3. Expansion of stem cell therapy centers and clinics
    • 5.1.2. Restraints
      • 5.1.2.1. Difficulties associated with performing stem cell therapy
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing advancements in stem cell therapy
      • 5.1.3.2. Surging approvals for marketing and clinical trials for stem cell therapies and treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical and safety issues of stem cell-based therapy
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Increasing uses of allogeneic and autologous stem cell therapy in chronic disease treatments
    • 5.2.2. Cell Source: Rising adoption of AD-MSCs and BM-MSCs in tissue remodeling and tissue repairing
    • 5.2.3. Therapeutic Application: Growing popularity of regenerative medicine in varied therapeutics areas
    • 5.2.4. End-User: Increasing uses of stem cell therapy in academics & research centers and hospitals offering effective, safe, and standardized treatment outcomes
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Stem Cell Therapy Market, by Type

  • 6.1. Introduction
  • 6.2. Allogeneic Stem Cell Therapy
  • 6.3. Autologous Stem Cell Therapy

7. Stem Cell Therapy Market, by Cell Source

  • 7.1. Introduction
  • 7.2. Adipose Tissue-Derived MSCs
  • 7.3. Bone Marrow-Derived MSCs
  • 7.4. Placental / Umbilical Cord-Derived MSCs

8. Stem Cell Therapy Market, by Therapeutic Application

  • 8.1. Introduction
  • 8.2. Cardiovascular Diseases Surgeries
  • 8.3. Inflammatory & Autoimmune Diseases
  • 8.4. Musculoskeletal Disorders
  • 8.5. Neurological Disorders
  • 8.6. Orthopedics & Rheumatoid
  • 8.7. Wounds & Injuries

9. Stem Cell Therapy Market, by End-User

  • 9.1. Introduction
  • 9.2. Academic & Research Centers
  • 9.3. Ambulatory Surgical Centers
  • 9.4. Biotechnology & Pharmaceutical Companies
  • 9.5. Hospitals & Clinics

10. Americas Stem Cell Therapy Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Stem Cell Therapy Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Stem Cell Therapy Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Fujifilm to Invest USD 200 Million in Cell Therapy Production
    • 13.3.2. Mesoblast Enters Collaboration for SR-aGVHD Trial After FDA Rejections
    • 13.3.3. Selecta Biosciences Announces Merger with Cartesian Therapeutics
    • 13.3.4. Takara Bio Enters into a License Agreement of RetroNectin with Fondazione Telethon ETS
    • 13.3.5. Bayer Opens First Cell Therapy Manufacturing Facility to Advance Regenerative Medicines on a Global Scale
    • 13.3.6. Novo Nordisk Foundation Invests USD 135 Million to Build Cell Therapy Plant
    • 13.3.7. BioLineRx Announces FDA Approval of APHEXDA (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma
    • 13.3.8. BlueRock Therapeutics and bit.bio Announce Collaboration and Option Agreement for the Discovery and Manufacture of Regulatory T Cell (Treg) based Therapies
    • 13.3.9. StemCyte Signs a Cooperation Agreement with a Cutting-edge U.S. immune Cell Therapy Company to Supply Drug Preparation Raw Materials for Allogeneic Modified Cell Therapy
    • 13.3.10. CIRM Invests USD 89 Million in Stem Cell and Gene Therapy Research
    • 13.3.11. Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production
    • 13.3.12. Novo Nordisk to Expand R&D Presence in Greater Boston Area
    • 13.3.13. Garuda Therapeutics Secures USD 62 Million Series B Financing to Advance Off-the-Shelf Blood Stem Cell Technology Platform
    • 13.3.14. BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients
    • 13.3.15. ReLive Biotechnologies, Ltd. Completes Asset Purchase of Co.Don AG and Series A Financing Led By SHC, Furthering its Ambition to Become the Global Player in Regenerative Therapies

Companies Mentioned

  • 1. 4D Molecular Therapeutics, Inc.
  • 2. Anterogen Co., Ltd.
  • 3. Astellas Pharma Inc.
  • 4. Athersys, Inc.
  • 5. Aurion Biotechnologies
  • 6. Beike Biotechnology Co., Ltd.
  • 7. BrainStorm Cell Therapeutics Inc.
  • 8. Bristol-Myers Squibb Company
  • 9. CellProthera
  • 10. Fate Therapeutics, Inc.
  • 11. Gamida Cell Ltd.
  • 12. Garuda Therapeutics
  • 13. Holostem Terapie Avanzate S.r.l.
  • 14. Jasper Therapeutics, Inc.
  • 15. JCR Pharmaceuticals Co., Ltd.
  • 16. Juvena Therapeutics Inc.
  • 17. Kangstem Biotech., Ltd.
  • 18. Kite Pharma, Inc. by Gilead Sciences, Inc.
  • 19. Lineage Cell Therapeutics, Inc.
  • 20. Lonza Group AG
  • 21. Mesoblast Ltd.
  • 22. Novo Nordisk A/S
  • 23. Plasticell
  • 24. ReNeuron Group PLC
  • 25. Sartorius CellGenix GmbH
  • 26. SQZ Biotechnologies Company
  • 27. Takara Bio Inc.
  • 28. U.S. Stem Cell Inc
  • 29. Umoja Biopharma
  • 30. Vericel Corporation

LIST OF FIGURES

  • FIGURE 1. STEM CELL THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. STEM CELL THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL STEM CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. STEM CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. STEM CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. STEM CELL THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL STEM CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. STEM CELL THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ALLOGENEIC STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AUTOLOGOUS STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ADIPOSE TISSUE-DERIVED MSCS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BONE MARROW-DERIVED MSCS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL STEM CELL THERAPY MARKET SIZE, BY PLACENTAL / UMBILICAL CORD-DERIVED MSCS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES SURGERIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INFLAMMATORY & AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL STEM CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ORTHOPEDICS & RHEUMATOID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL STEM CELL THERAPY MARKET SIZE, BY WOUNDS & INJURIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. STEM CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 195. STEM CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023